LUNG Stock Summary and Trading Ideas (Pulmonx | NASDAQ:LUNG)

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Pulmonx trades on the NASDAQ stock market under the symbol LUNG.

As of March 10, 2026, LUNG stock price declined to $1.78 with 661,184 million shares trading.

LUNG has a beta of 0.72, meaning it tends to be less sensitive to market movements. LUNG has a correlation of 0.01 to the broad based SPY ETF.

LUNG has a market cap of $73.63 million. This is considered a Micro Cap stock.

Last quarter Pulmonx reported $23 million in Revenue and -$.25 earnings per share. This beat revenue expectation by $865,002 and exceeded earnings estimates by $.14.

In the last 3 years, LUNG traded as high as $14.84 and as low as $1.31.

The top ETF exchange traded funds that LUNG belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

LUNG has underperformed the market in the last year with a return of -76.1%, while the SPY ETF gained +18.8%. In the last 3 month period, LUNG fell short of the market, returning -23.4%, while SPY returned -0.6%. However, in the most recent 2 weeks LUNG has outperformed the stock market by returning +20.6%, while SPY returned -0.8%.

LUNG support price is $1.71 and resistance is $1.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LUNG shares will trade within this expected range on the day.